Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qilu Buxue Granule for prevention and treatment of chemotherapy-associated leukopenia in lung adenocarcinoma
ChiCTR1900022643Phase 4Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Apr 2019
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Qilu Buxue Granule in leukopenia and Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoints: White blood cell count and Neutrophil count. Started Apr 2019; status: recruiting.
02
Drugs
Qilu Buxue Granule
03
Conditions
leukopeniaNon-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900022643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022643.